Medicenna Therapeutics Corp. MDNA.TO

MDNA.TO Company Overview

Medicenna Therapeutics Corp. is a Canadian biotechnology company focused on the development of engineered interleukin (IL)-based immunotherapies for cancer and autoimmune diseases. The company operates within the biotechnology and immuno-oncology sectors and develops proprietary cytokine therapies designed to selectively activate immune responses while reducing toxicity associated with traditional cytokine treatments. Medicenna is publicly traded on the Toronto Stock Exchange under the ticker MDNA and also trades on the Nasdaq Capital Market under the symbol MDNA.

The company’s primary business lines center on its proprietary “Superkine” and “Empowered Superkine” platforms, which engineer cytokines such as IL-2, IL-4, and IL-13 to improve therapeutic targeting and efficacy. Its lead clinical-stage asset has been MDNA11, an IL-2 Superkine program designed to preferentially activate anti-tumor immune cells while minimizing stimulation of regulatory T cells. Medicenna’s strategy has focused on developing differentiated immunotherapies with potentially improved safety profiles compared with earlier cytokine-based cancer treatments. The company originated from research conducted at the University Health Network in Toronto and evolved from an early-stage research enterprise into a clinical-stage biotechnology company through licensing agreements, platform development, and public market financing.